Author

Barry Johns

Observed names: B Johns, B. R. Johns, BARRY R. JOHNS, Barry R Johns, Barry R. Johns, Barry Russel Johns

Observed institutions: Mercer University, Emory University, University of Oxford, Stanford Medicine, MRC Population Health Research Unit, Winship Cancer Institute, Stanford University

OpenAlex ID: A5000851382

Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes

2021 · Sue A. Brown, Gregory P. Forlenza, et al. · Diabetes Care · 297

RNA Interference With Zilebesiran for Mild to Moderate Hypertension

2024 · George L. Bakris, Manish Saxena, et al. · JAMA · 163

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

2023 · PK Judge, N Staplin, et al. · The Lancet Diabetes & Endocrinology · 137

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

2023 · N Staplin, R Haynes, et al. · The Lancet Diabetes & Endocrinology · 114

Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension

2025 · Akshay S. Desai, Adam D. Karns, et al. · JAMA · 65

Metabolic syndrome, insulin resistance and kidney function in non-diabetic individuals

2011 · B. R. Johns, A. C. Pao, et al. · Nephrology Dialysis Transplantation · 33

Real-World Assessment of Glycemic Control After V-Go® Initiation in an Endocrine Practice in the Southeastern United States

2014 · Barry R. Johns, Thomas C. Jones, et al. · Journal of Diabetes Science and Technology · 15

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

2025 · Junwen Zhou, Claire Williams, et al. · EClinicalMedicine · 11

Estimates of Insulin Secretory Function in Apparently Healthy Volunteers Vary as a Function of How the Relevant Variables Are Quantified

2011 · Barry R Johns, Fahim Abbasi, et al. · Clinical Chemistry · 8

PPAR-γ agonists, insulin resistance and dyslipidemia: not a simple relationship

2010 · Barry R Johns, Gerald M Reaven · Clinical Lipidology · 5

Interferon Alfa-2b or Not 2b? Significant Differences Exist in the Decision-Making Process between Melanoma Patients Who Accept or Decline High-Dose Adjuvant Interferon Alfa-2b Treatment

2007 · TRACY B. BRAMLETTE, DAVID H. LAWSON, et al. · Dermatologic Surgery · 3

Tu1078: LOW-DOSE RIFABUTIN TRIPLE THERAPY (RHB-105) MAINTAINS HIGH HELICOBACTER PYLORI ERADICATION RATES AND SHOWS FAVORABLE SAFETY AND EFFICACY IN SUBJECTS WITH DIABETES MELLITUS

2022 · Colin W. Howden, Barry R. Johns, et al. · Gastroenterology

238 Metabolic Syndrome, Insulin Resistance, and Kidney Function in Nondiabetic Individuals

2011 · Barry Johns, Alan Pao, et al. · American Journal of Kidney Diseases

Works count: 13

Citation count: 851

H-index: 8

I10-index: 8